Gilead Sciences Inc

Gilead's Corporate Responsibility Committee (CRC) is responsible for the strategic direction, accountability and review of the impact of our ESG activities. The CRC comprises leadership across Public and Government Affairs, Human Resources, Legal, Finance, Medical Affairs, Commercial and Manufacturing. These cross-functional executives are responsible for obtaining wide organizational buy-in while also providing regular feedback to Gilead's senior leadership team and Board of Directors about ESG activities. Our Nominating and Corporate Governance Committee of the Gilead Board of Directors has primary oversight of our ESG program as part of its charter. Our full Board exercises risk oversight directly and through its committees. The committees, as well as management, provide regular updates on delegated areas of oversight, specific ESG material risks and legal developments. To further demonstrate Gilead's robust oversight of our corporate responsibility and sustainability efforts, the majority of our Board members have ESG experience. Our management-led CRC meets quarterly and is tasked with managing ESG issues and, in consultation with senior leadership, driving forward our ESG goals and strategy.

A culture of robust governance and accountability is at the heart of Gilead's ESG progress. Our Board's Nominating and Corporate Governance Committee oversees our ESG commitments and progress, and executive compensation is tied to achieving ambitious ESG goals. [...] Our Corporate Responsibility Committee shepherds our ESG vision and builds accountability for driving positive social and environmental change across our company and supply chain. Composed of leaders from Public and Government Affairs, Human Resources, Legal, the CFO organization, Commercial and Manufacturing, the committee is responsible for reviewing and making decisions on ESG-related strategies, stakeholder engagement, reporting, risk mitigation and other relevant activities. The Nominating and Corporate Governance Committee of our Board reviews and oversees our ESG program.

Our Nominating and Corporate Governance Committee of the Gilead Board of Directors has primary oversight of our ESG program as part of its charter. Our full Board exercises risk oversight directly and through its committees. The committees, as well as management, provide regular updates on delegated areas of oversight, specific material risks and legal developments. To further demonstrate Gilead's robust oversight of our corporate responsibility and sustainability efforts, the majority of our Board members have ESG experience. Our management-led Corporate Responsibility Committee meets quarterly and is tasked with managing ESG issues and, in consultation with senior leadership, driving forward our ESG goals and strategy. [...] A key piece of Gilead's ESG efforts is our focus on governance. Gilead's Corporate Responsibility Committee (CRC) is responsible for the strategic direction, accountability and review of the impact of our ESG activities. The CRC draws from cross-functional leadership across Public and Government Affairs, Human Resources, Legal, Finance, Medical Affairs, Commercial and Manufacturing. These cross-functional executives ensure there is wide organizational buy-in while also providing regular feedback to Gilead's Board of Directors about ESG activities. The CRC is currently guiding Gilead through our first double materiality assessment to identify the potentially material ESG topics from an impact and financial perspective and to assess the potential impact and opportunities. Upon completion of the double materiality assessment, we look forward to keeping our employees and stakeholders informed of any material changes to our ESG strategy.

In addition to Gilead and its employees engaging with policymakers, the company participates in the public policy process through its involvement with trade associations. By working with other companies in our industry and with similar interests, we can amplify our voice on the issues that matter most. Trade associations also add value by creating a venue to interact with our peer companies and share best practices across the industry. The Nominating and Corporate Governance Committee ("NCGC") of the Gilead Board of Directors is responsible for providing oversight over Gilead's involvement with trade associations and reviews all payments to trade associations. Of course, our policies and priorities will never align completely with any given trade association, which has to answer to all of its members, but we do regularly evaluate our involvement with trade associations. If a trade association to which we belong takes positions that run contrary to our policy interests, Gilead Government Affairs, in coordination with Gilead senior management, will seek to guide the trade association's position into alignment with our own. If Gilead management determines that the misalignment is material, it would present such misalignment to the NCGC to review and make a final determination on Gilead's course of action. The NCGC would weigh the misalignment against the value that the trade association membership brings, and consider reducing or eliminating our involvement with the trade association. Recently we conducted a more formal review of our most significant trade association relationships. We evaluated certain policy positions of each trade association to which the portion of Gilead's annual payments that are not deductible under Section 162(e) of the Internal Revenue Code exceed $25,000. Those trade associations are Biotechnology Innovation Organization, California Life Sciences, Pharmaceutical Research and Manufacturers of America, and the United States Chamber of Commerce. We analyzed the trade associations' positions on Gilead's core public policy priorities (Drug Pricing and Access, and Intellectual Property Rights) and two other important company priorities: Climate Change, and Diversity, Equity and Inclusion. We then evaluated the congruency between the trade associations' positions and those of Gilead. After conducting the review, we are pleased to report the trade associations are all generally in close alignment.

Describe the process(es) your organization has in place to ensure that your engagement activities are consistent with your overall climate change strategy[…]Gilead participates in the political process by contributing prudently to state and local candidates and political organizations when such contributions are permitted by state and local law. Generally, contributions are made to officeholders and candidates based on several criteria, including, policy positions that reflect the interests of Gilead, its employees or the communities it serves; representation of geographic area where Gilead's employees and facilities are located; ability to be elected; and the need for financial assistance. Gilead's priorities for making political expenditures with corporate funds include furthering public health policy and scientific and health innovation.

Process for ensuring a common approach to multiple climate engagement activities: Gilead's Nominating and Corporate Governance Committee reviews all of the company's political expenditures and confirms that all political expenditures are consistent with the company's policies on a periodic basis. The Nominating and Governance Committee also reviews all payments to trade associations. In addition, outside counsel provides a periodic review of Gilead's political activity across the organization.

Does your organization have a public commitment or position statement to conduct your engagement activities in line with the goals of the Paris Agreement?[…]No, and we do not plan to have one in the next two years